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Abstract
Background: Due to high survival rates and the relatively small benefit of adjuvant therapy, the application of
personalized medicine (PM) through risk stratification is particularly beneficial in early breast cancer (BC) to avoid
unnecessary harms from treatment. The new 21-gene assay (OncotypeDX, ODX) is a promising prognostic score
for risk stratification that can be applied in conjunction with Adjuvant!Online (AO) to guide personalized
chemotherapy decisions for early BC patients. Our goal was to evaluate risk-group specific cost effectiveness
of adjuvant chemotherapy for women with early stage BC in Austria based on AO and ODX risk stratification.
Methods: A previously validated discrete event simulation model was applied to a hypothetical cohort of 50-year-old
women over a lifetime horizon. We simulated twelve risk groups derived from the joint application of ODX and AO and
included respective additional costs. The primary outcomes of interest were life-years gained, quality-adjusted life-years
(QALYs), costs and incremental cost-effectiveness (ICER). The robustness of results and decisions derived were tested in
sensitivity analyses. A cross-country comparison of results was performed.
Results: Chemotherapy is dominated (i.e., less effective and more costly) for patients with 1) low ODX risk independent
of AO classification; and 2) low AO risk and intermediate ODX risk. For patients with an intermediate or high AO risk and
an intermediate or high ODX risk, the ICER is below 15,000 EUR/QALY (potentially cost effective depending on the
willingness-to-pay). Applying the AO risk classification alone would miss risk groups where chemotherapy is dominated
and thus should not be considered. These results are sensitive to changes in the probabilities of distant recurrence but
not to changes in the costs of chemotherapy or the ODX test.
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Conclusions: Based on our modeling study, chemotherapy is effective and cost effective for Austrian patients with an
intermediate or high AO risk and an intermediate or high ODX risk. In other words, low ODX risk suggests chemotherapy
should not be considered but low AO risk may benefit from chemotherapy if ODX risk is high. Our analysis suggests that
risk-group specific cost-effectiveness analysis, which includes companion prognostic tests are essential in PM.
Keywords: Cost-effectiveness analysis, Breast cancer, Adjuvant chemotherapy, Adjuvant!Online, OncotypeDX, Discrete
event simulation, Personalized medicine, Decision analysis, Cost-utility analysis
Background
‘Personalized medicine’ (PM) is an increasingly relevant
concept in clinical oncology. The term PM refers to an
evolving approach to clinical decision making which
seeks “to improve the stratification and timing of health
care by utilizing biological information and biomarkers
on the level of molecular disease pathways, genetics,
proteomics as well as metabolomics” [1]. Although gen-
omic information is considered to be the cornerstone of
this discipline [2], clinical and sociodemographic charac-
teristics of the patient and individual preferences can
also be utilized to personalize medicine [3]. Because
treatment strategies can be tailored in such a way that
only patients who stand to benefit receive treatment [4],
PM is particularly relevant in diseases, such as breast
cancer, where in some cases the potential adverse effects
may outweigh the benefits of treatment [5].
Breast cancer is among the most common types of
cancer and a leading cause of cancer deaths in women.
In Austria, breast cancer accounts for 30% of all tumors
and for 16% of all cancer deaths in women [6]. The inci-
dence of breast cancer in Austria in 2012 was about 76
cases per 100,000 women [6]. One of 13 females born in
2011 will develop breast cancer by the age of 75 years
[7]. Aside from a small percentage of familial breast can-
cer, the risk factors for this malignancy are rather broad
and vague: e.g., age, early menarche, late menopause,
and obesity [8]. Although many treatment options are
available [9, 10], the standard of care for early breast
cancer is surgical resection, often followed by adjuvant
radiation. Additional adjuvant systemic therapy depends
on the hormone receptor status, such as estrogen recep-
tor (ER) status, postmenopausal status, human epider-
mal growth factor receptor 2/neu (HER-2/neu) status,
stage of the disease and co-morbidities.
For women with lymph node negative, estrogen recep-
tor (ER) positive early-stage breast cancer who have rela-
tively low recurrence risk adjuvant chemotherapy
decision is complex and uncertain. While adjuvant sys-
temic therapy can be beneficial for women at higher risk
of a distant recurrence, it can cause more harm than
benefit for low risk patients. Several prognostic tests are
available to help identify women most likely to benefit
from adjuvant systemic therapy in order to help guiding
adjuvant therapy decision-making. For example,
Adjuvant!Online is a free online tool that estimate risks
and benefits of adjuvant therapy after breast cancer
surgery based on factors, such as the patient’s stage,
pathologic features, age and comorbidity level [11].
Mammaprint and OncotypeDX (ODX) are gene expres-
sion assays that “combine the measurements of gene ex-
pression levels within the tumor to produce a number
associated with the risk of distant disease recurrence.
These genetic tests aim to improve on risk stratification
schemes based on clinical and pathologic factors cur-
rently used in clinical practice” [12]. As clinical decisions
are increasingly based on the predictions of these tests,
the additional costs should be considered in decision
analyses of cancer management and treatment, similar
to other companion diagnostics in PM [13].
Several studies have been conducted to evaluate the
cost effectiveness or cost utility of different chemo-
therapy regimens. In our systematic literature search
in CRD (Center for Reviews and Dissemination) [14],
we found 24 cost-effectiveness studies that evaluate
various chemotherapeutic regimens including capecit-
abine, cyclophosphamide, docetaxel, doxorubicin, epir-
ubicin, eribulin, flourouracil, gemcitabine, ixabepilone,
methotrexate, mytomycin, paclitaxel, vinblastine, and
vinorebline. These studies were performed in the
healthcare contexts of China, Canada, Germany,
France, Italy, South Korea, Spain, UK, USA, The
Netherlands, and Thailand. In particular, none were
conducted for the Austrian healthcare context and
none of these take into account personalized treat-
ment decisions based on risk classification by AO and
the new 21 gene assay ODX.
Our study focused on patients with ER and/or proges-
terone receptor (PR) positive, HER-2/neu negative and
lymph node negative early breast cancer for whom AO
and ODX risk classification may provide additional in-
formation that impacts decision-making. An advanced
literature search conducted in PubMed [15] yielded no
further studies on the combined prognostic approach of
AO and ODX for these risk groups. Only Paulden et al.
evaluate in a secondary analysis cost effectiveness of
chemotherapy within risk groups according to AO and
ODX. However, this was in a Canadian setting which
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differs from Austria (e.g., due to provided chemotherapy
regimens and costs) [16].
The goal of the current study was to evaluate risk-
group specific cost effectiveness of adjuvant chemother-
apy for Austrian women with resected ER and/or PR
positive, HER-2/neu negative, and lymph node negative
early breast cancer. All potential risk groups according
to the joint application of AO and ODX are considered.
Additionally, we then compare these results to those
from the Canadian study by Paulden et al. [16].
Methods
Modeling Framework
To analyze adjuvant test-treatment strategies for early
breast cancer, we applied a decision-analytic computer
simulation model [17] previously developed within our re-
search center ONCOTYROL – Center for Personalized
Cancer Medicine [18] (hereafter the “Oncotyrol breast can-
cer model”). The model validation and first application
were recently published elsewhere [19, 20]. In this new
model application, a hypothetical cohort of 50-year-old
women diagnosed with ER and/or PR positive, HER-2/neu
negative, lymph node negative breast cancer was simulated.
We adopted a health care system perspective and lifetime
horizon for this analysis. Outcomes of interests included
survival (number of life years; LY), quality of life (number
of quality-adjusted-life years; QALY), total costs (EUR) and
incremental cost-effectiveness ratios (EUR/QALY). Costs
and effects were discounted by 5% per year [21]. According
to the ISPOR-SMDM guidelines [22], the model was im-
plemented using a discrete event simulation approach
(ARENAVersion 13.90.00000, Rockwell Automation). This
approach allows for individual patient pathways to be
determined by multiple characteristics and test results, in-
dividual patient pathways to be recorded and time depend-
encies to be accounted for.
For reporting our modeling study, we followed the
Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) Statement [23].
Model structures
The Oncotyrol breast cancer model is divided into dif-
ferent modules that describe the test-treatment strat-
egies and the respective pathways of patients, their
health states and key health events (Fig. 1).
In the beginning of the simulation (Module 1), patients
enter the model, patient characteristics are assigned
(age, time of death from other causes) and their AO risk
score (individualized breast cancer specific mortality
[BCSM]) and ODX risk classification (recurrence risk
score [RS]) are calculated (BCSM: L ‘low’ BCSM < 9%, I
‘intermediate’ 9% ≤ BCSM < 17% or H ‘high’ BCSM ≥ 17%
[24]; RS: L ‘low’ RS < 18, I ‘intermediate’ 18 ≤ RS < 30,
H ‘high’ RS ≥ 30, N ‘RS not applied’). The costs and ben-
efits of chemotherapy are quantified for each of the
twelve combinations of risk classifications (where the
first letter represents AO and second letter represents
ODX: L-L, L-I, L-H, L-N, I-L, I-I, I-H, I-N, H-L, H-I, H-
H, H-N). Two hypothetical cohorts were simulated in
which all patients within these risk groups are assumed
to receive or to not receive chemotherapy. Patients that
pursue chemotherapy continue to Module 2 where
chemotherapy and its associated adverse events (neutro-
penia, fever, infections, pain, nausea and gastrointestinal
complications) are modeled. After chemotherapy, these
patients are considered recurrence-free and are treated
Fig. 1 Schematic model structure. (Abbreviations: ADE-adverse drug event, LY-life years gained, QALY-quality adjusted-life years, AO-Adjuvant!Online, ODX-
OncotypeDX), L-Low, Int./I-intermediate, H-High, combinations of risk classification (first letter representing Adjuvant!Online, second letter representing
OncotypeDX: L-L, L-I, L-H, L-N, I-L, I-I, I-H, I-N, H-L, H-I, H-H, H-N). Source: adapted from Jahn et al. Lessons learned from a cross-model validation between a
discrete event simulation model and a cohort state-transition model for personalized breast cancer treatment. Med Decis Making. 2016;36(3):375–390.
Copyright © 2016 by Society for Medical Decision Making. Reprinted by permission of SAGE Publications, Inc.
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with aromatase inhibitors or tamoxifen for five subse-
quent years (Module 3). In addition, patients who do not
receive chemotherapy enter Module 3 directly. Patients
who face disease recurrence continue to Module 4
where further diagnostics and treatments are considered.
We assume that patients with a distant recurrence re-
main in this health state and in Module 4 until they die
from breast cancer. Throughout the entire simulated
pathway, LYs, QALYs and costs are accumulated, and
analyzed in the statistical module. In addition, all pa-
tients may die due to other causes at any time point and
consequently leave the model.
Model parameters
A detailed description of model parameters is provided
elsewhere [19] and an overview of model parameters and
sources are shown in Additional file 1: Table S1.
With respect to chemotherapeutic agents, we assumed
all patients receive three cycles of FEC (5-fluorouracil,
epirubicin, cyclophosphamide) followed by three cycles
of DOC (docetaxel) [9]. After completion of adjuvant
chemotherapy, all patients also received an aromatase
inhibitor (anastozole, letrozole or exemestane) for five
years. In cases in which no chemotherapy was provided,
an aromatase inhibitor was started immediately.
Risk-group specific time to recurrence estimates
were derived from Paulden et al. [16]. Treatment as-
sumptions about distant recurrence were based on
chart reviews by a senior gynecologist at Innsbruck
Medical Hospital. The probability of death due to
breast cancer in patients with distant recurrence was
assumed to be identical in all patients regardless of
the ER/PR status or the patient’s personal cancer
history (median survival 25.8 months from time of
diagnosis of recurrence [25]). Fatal toxicity of chemo-
therapy includes those patients who develop chemo-
therapy related acute myeloid leukemia (AML). All-
cause mortality was applied throughout the entire
simulated time horizon. Data were extrapolated using
national life tables from Statistics Austria [26].
As ODX is currently not reimbursed in Austria, we relied
on the manufacturer’s suggested retail price [27]. AO is
available to medical experts free of charge [11]. We in-
cluded direct costs for chemotherapy and related side ef-
fects (costs of chemotherapeutic agents, other supportive
medications, such as pegfilgrastim and tropisetron,
hospitalization, laboratory studies, and human resources),
as well as costs of cancer follow-up, diagnosis and treat-
ment of recurrent cancer [10, 25, 28] [Walter E: IPF, Vienna
2012, Report, unpublished]. Drug costs were based on
pharmacy hospital prices. Utility weights were based on a
recent cross-sectional observational study using the Euro-
Qol five dimension questionnaire (EQ-5D) [29].
Model validation
Model validation is a key modeling step for judging a
model’s accuracy in making accurate predictions. Follow-
ing the current ISPOR-SMDM best practice recommen-
dations, the model was validated using face validation,
internal validation and cross-model validation [30]. Fur-
ther details are provided in Jahn et al. [20].
Analysis
In the base-case analysis, we estimated discounted effects
(LYs, QALYs) and costs of adjuvant chemotherapy in 12
different patient risk groups classified according to their
AO (first letter) and ODX (second letter) risk classification
(L-L, L-I, L-H, L-N, I-L, I-I, I-H, I-N, H-L, H-I, H-H, H-
N). 100,000 patients were needed in the simulation in
order to achieve stable results [20].
For each risk group, the simulation was run twice, the
first assuming chemotherapy received by the patient and
the second run assuming no chemotherapy received.
The ICER was calculated by calculating the difference in
discounted costs divided by the difference in discounted
QALYs for these two alternatives. If one strategy is less
effective but more expensive, then it is considered domi-
nated and should not be considered. If chemotherapy is
more effective but also more expensive, as compared to
no chemotherapy, the ICER expresses the additional
costs for one QALY gained. Chemotherapy is considered
cost effective if the ratio is less than the willingness-to-
pay (WTP) threshold.
As there is currently no explicit willingness-to-pay
threshold for health technologies in Austria, we assumed
a WTP of 50,000 EUR (alternatively 100,000 EUR) to
test the robustness of our results and respective deci-
sions in sensitivity analyses.
Parameter uncertainty was estimated using extensive
deterministic one way sensitivity analyses on several pa-
rameters including age (40; 50; 70), discount rate (0;
2.5%; 5%), the cost of chemotherapy (+/− 10%), the cost
of an ODX test set (+/− 10%), utilities (95% confidence
intervals (CI) assuming a beta distribution), and the
probability of distant recurrence (95% CI, assuming a
beta distribution).
In a cross-country comparison, results were compared
to the results of the Canadian modeling study by Paul-
den et al. [16] who applied a similar model structure. In
contrast to our model, the Canadian model was designed
as a probabilistic state-transition Markov [31] model for
that particular health care setting which differ from
Austria. For example, different chemotherapy regimens
were considered (low risk patients: CMF (Cyclophospha-
mide, Methotrexate, 5-fluorouracil), intermediate risk
patients: TC (Docetaxel, Cyclophosphamide), high risk
patients: FEC-D 5-fluorouracil, Epirubicin, Cyclophos-
phamide, Docetaxel)). A list of parameter values for this
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model is provided in the Additional file 1. The modeling
framework and the model structure are described else-
where in greater detail [16].
Results
Base case
The results of the base-case analysis for the Austrian and the
Canadian settings are displayed in Table 1. For each risk
group, two lines depict the estimated, discounted LYs, QALYs
and costs when chemotherapy is provided and when it is not.
The ICER summarizes the results of chemotherapy or none.
The results for the Austrian setting indicate that chemo-
therapy is dominated in the risk groups L-L (low AO, low
ODX), L-I (low AO, intermediate ODX), I-L (intermediate
AO, low ODX) and H-L (high AO, low ODX). Patients in
these risk groups do not on average benefit from
chemotherapy with respect to the clinical outcomes (LYs,
QALYs). These results are consistent with the results for the
Canadian setting with the exception of the L-I risk group
(low AO and intermediate ODX).
In high risk ODX patients, chemotherapy seems to clearly
be cost effective because an additional QALY can be gained
at a low additional cost (ICER less than 3500 EUR/QALY).
Chemotherapy is also cost effective in patients with an inter-
mediate ODX risk and an intermediate or high AO risk
chemotherapy with a WTP threshold of 15,000 EUR/QALY.
These results are also consistent with the results from the
Canadian setting. For patients in our model that are tested
only with AO, chemotherapy is mainly cost effective with
the exception of those who are AO low risk (L-N). These re-
sults differ slightly to the Canadian setting where chemo-
therapy for L-N patients is cost effective.
Table 1 Discounted life-years, QALYs and incremental cost-effectiveness ratios of chemotherapy in the Austrian setting versus Canadian
setting
Austrian setting Canadian setting
Risk category Chemo LYs QALYs Costs
(€)
ICER
(€/QALY)
LYs QALYs Costs
(€)
ICER
(€/QALY)AO ODX
Low Low No 15.51 12.04 11,021 D 15.36 11.93 10,088 D
Yes 15.16 11.65 23,383 15.14 11.69 11,817
Low Int. No 14.96 11.61 12,063 D 14.85 11.52 11,279 61,861
Yes 15.05 11.57 23,608 15.04 11.61 16,562
Low High No 12.06 9.31 17,520 3361 12.07 9.32 17,368 3118
Yes 14.73 11.31 24,240 14.73 11.37 23,743
Low N/A No 14.80 11.48 9230 566,277 14.69 11.40 8347 3768
Yes 14.97 11.50 20,554 14.96 11.55 8925
Int. Low No 15.21 11.80 11,557 D 15.10 11.72 10,708 D
Yes 15.02 11.54 23,641 15.01 11.59 12,105
Int. Int. No 13.71 10.62 14,421 13,504 13.69 10.60 13,872 4094
Yes 14.77 11.34 24,163 14.78 11.40 17,150
Int. High No 9.45 7.25 21,733 698 9.51 7.30 22,401 416
Yes 14.61 11.21 24,500 14.60 11.26 24,049
Int. N/A No 12.63 9.77 13,372 4790 12.63 9.76 12,927 548
Yes 14.78 11.35 20,960 14.79 11.41 13,833
High Low No 15.21 11.81 11,561 D 15.09 11.71 10,721 D
Yes 15.03 11.55 23,666 15.01 11.59 12,116
High Int. No 13.76 10.66 14,471 14,496 13.66 10.58 13,969 3940
Yes 14.75 11.33 24,143 14.77 11.40 17,186
High High No 9.43 7.23 21,815 676 9.48 7.27 22,474 400
Yes 14.60 11.21 24,502 14.59 11.26 24,068
High N/A No 12.09 9.34 14,257 3097 12.08 9.33 14,078 2816
Yes 14.88 11.43 20,729 14.87 11.48 20,121
Abbreviations: AO Adjuvant!Online, ODX OncotypeDX, Int. Intermediate, LYs life years, QALYs quality-adjusted life-years, ICER incremental cost-effectiveness ratio,
N/A ODX test not applied
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Sensitivity analyses
Results of the sensitivity analyses are displayed in Table 2
(assuming WTP 50,000 EUR/QALY) and in the additional
files (Additional file 2: Table S2A, Additional file 3: Table
S2B, Additional file 4: Table S2C and Additional file 5:
Table S2D assuming WTP 100,000 EUR/QALY). We ran
the analysis for the four main risk groups (ODX low,
ODX intermediate, ODX high, ODX not provided). In
each block, we considered the respective AO risk in three
columns. The first row in the table provides the results of
the cost effectiveness of chemotherapy for each risk group
in the base case. For example, for patients that have a low
risk according to ODX and a low risk according to AO (L-
L), chemotherapy was dominated (D) in the base case. In
the following section, we display the results of the lower
and upper bound when the parameters are varied. For ex-
ample, we first consider a patient cohort age 40 (lower
bound) and a patient cohort age 70 (upper bound). For
the above risk group L-L, we observe that chemotherapy
is still dominated, even if we vary the parameter age
within the range of 40–70 years. We marked parameters
depending on their impact on cost-effectiveness results
and the following decisions: a) if the parameters that were
changed led to the same decision based on the cost-
effectiveness result, we use a white background, b) if those
parameters that were varied led to a different decision
based on the cost-effectiveness results, cells were colored
with a dark grey. These were done assuming a WTP
threshold of 50,000 EUR/QALY (Table 2) or 100,000
EUR/QALY (Additional file 2: Table S2A, Additional file
3: Table S2B, Additional file 4: Table S2C and Additional
file 5: Table S2D).
In summary, in one-way sensitivity analyses results
were robust to changes in utilities, costs of chemother-
apy and the genetic test ODX, a discount rate of 2.5%
and patients at 40 years of age. For older age groups, the
decision would be similar assuming a WTP of 65,000
EUR/QALY. The results, however, were sensitive to the
probabilities of distant recurrence (with and without
chemotherapy) especially within the risk groups L-I, I-L,
I-I, H-L, H-I, L-N.
In the risk groups L-I, I-L and H-L, chemotherapy was
dominated in the base case but was cost effective when
the probabilities of distant recurrence were varied. In
the risk groups I-I and H-I, chemotherapy was domi-
nated when the probability of distant recurrence was
varied. L-N became cost effective when the lower range
of the probability of distant recurrence following chemo-
therapy was used.
Discussion
In our cost-effectiveness analysis of adjuvant chemother-
apy for early stage breast cancer patients, we evaluated
upfront testing within the cancer management process
Table 2 Sensitivity analyses of cost effectiveness of chemotherapy
Abbreviations: AO Adjuvant!Online, D dominated, dist. rec. distant recurrence,
N/A not applied, bold numbers represent base case values
a/bbase case ±2% for each risk group with/without chemotherapy, respectively
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similar to the evaluation of companion diagnostics. Our
analysis shows that in the Austrian setting chemotherapy
is effective and potentially cost effective for patients with
an intermediate or high risk of disease according to
ODX, independent from the AO risk classification (with
the only exception of risk group L-I). In other words,
low ODX risk suggests chemotherapy should not be
considered but low AO risk may benefit from chemo-
therapy only if ODX risk is high.
Our results demonstrate that if the ODX test was not
applied, chemotherapy would be considered cost effect-
ive for AO intermediate and high risk patients. However,
based on the additional results of the ODX test, chemo-
therapy is dominated (less effective and more costly) for
ODX low risk patients within these AO risk groups.
Therefore, in the decision process we would not favor
chemotherapy and consequently, reduce harms and costs.
For low risk patients per the AO test, chemotherapy
would very likely not be cost effective. However, after
taking into account the additional information provided
by the ODX test as well as the additional costs of this test,
chemotherapy became cost effective for AO low and ODX
high risk patients. In particular, these patients would
greatly benefit from chemotherapy, both clinically and
economically. In summary, our results demonstrate the
importance of considering personalized information and
additional costs in the evaluation of chemotherapy.
Sensitivity analyses demonstrate that the results are
relatively robust with respect to the decisions about al-
most all model parameters except for the probability of
distant recurrence within the risk groups L-I, I-L, I-I, H-
L, H-I, L-N. For high risk patients per ODX and those
classified only based on AO, the results are robust.
The advantage of our modeling approach is that, in
addition to providing risk group-specific cost effectiveness
of chemotherapy, we are also able to evaluate the effective-
ness and cost effectiveness of the risk classification tools as
previously shown [19]. Within this analysis, we considered
that decisions regarding chemotherapy are based on the
risk classification and additional factors. Therefore, only a
percentage of patients would finally agree or not agree on
chemotherapy in the respective risk groups. Our modular
modeling structure approach allows one to adapt the model
to evaluate additional test information or other innovative
personalized test-treatment decisions.
Our results are consistent with the analysis of Paulden
et al. [16] that showed a similar cost effectiveness of
chemotherapy in the Canadian setting when using com-
parable risk classifications. In our systematic literature
review, we identified no cost-effectiveness study for
Austria nor any study that applied Adjuvant!Online or
OncotypeDX. We identified four studies that sought to
evaluate the same adjuvant chemotherapy regimen (FEC
and TC). However, only one of these studies compared
chemotherapy versus no chemotherapy. Campbell et al.
[32] compared four strategies including one strategy
without chemotherapy and three with different chemo-
therapy regimens. They found that “with an average to
high risk of recurrence […], FEC-D appeared most cost
effective assuming a threshold of £20,000 per QALY
for the National Health Service (NHS). For younger
low risk women, E-CMF (epirubicin, cyclophosphamide,
methotrexate, fluorouracil) /FEC tended to be the optimal
strategy and, for some older low risk women, the
model suggested a policy of no chemotherapy was
cost effective” [32]. These results were consistent with
our results that also suggest that adjuvant chemo-
therapy is not cost effective in low-risk groups but is in
high risk groups.
In Austria, there is currently no explicit threshold for
health technologies to be considered cost effective. In
other countries, thresholds vary and they are rarely disease
or cancer specific. For example, in Canada, an oncology-
specific ceiling threshold value of C$75,000 (equivalent to
EUR 51,528) has been suggested and NICE (National In-
stitute for Health and Care Excellence) provides a general
threshold in 2012 of £18,317/QALY (EUR 23,180) that
can be revised based on other factors [33].
Our study has several limitations. Although modeling
studies allow information to be combined from different
sources, we included as much Austrian data and local in-
formation on cancer management as possible. However,
due to a lack of information about utility parameters and
estimates for the risk of distant recurrence, we applied re-
sults from international studies. The underlying causes of
hospitalizations were adapted for the Austrian context
based on information of local clinical experts.
For some of the risk groups of interest, the decision
regarding the provision of adjuvant chemotherapy may
be predefined. However, we analyzed all potential groups
for completeness. In addition to AO and ODX, there are
other risk classification scores and genetic tests that may
be used for this purpose. Since AO is continuously up-
dated and free of charge, it was considered as first
choice. Although not currently covered, ODX is a gen-
etic test that has shown convincing analytical and clin-
ical validity and therefore is likely to be implemented in
clinical practice in Austria in the near future.
The ability to compare these results with the Canadian
study results is limited due to the different health care
settings (e.g., type of chemotherapy recommended, fol-
low up treatment, cost structure), however, the results
fall in a reassuringly similar direction.
In the future, our analysis could be applied in cost-
effectiveness analyses based on risk classifications that
are obtained from combinations of various multi-
parameter molecular marker assays. At the fourteenth
St. Gallen International Breast Cancer Conference, one
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expert panel discussed the role of multi-parameter mo-
lecular marker assays for prognosis and their value in
selecting patients who require chemotherapy. “Oncotype
DX®, MammaPrint®, PAM-50 ROR® score, EndoPredict®
and the Breast Cancer Index® were all considered use-
fully prognostic for years 1-5” [34]. Beyond 5 years, re-
ports suggest that these tests are prognostic [34]. The
Panel agreed the PAM50 ROR® score to be clearly prog-
nostic beyond 5 years. However, a clear majority rejected
the prognostic value of MammaPrint®. For Oncotype
DX®, the majority of the panel agreed with the potential
value in predicting the usefulness of chemotherapy. Im-
proved evidence supporting our modeling study will be
provided by the TAILORx trail. After the full TAILORx
trial results on ODX become available, we will rerun the
analysis using updated input parameters including the
probabilities of distant recurrence. Although there are
promising alternative tests that allow personalized treat-
ment decisions, multi-parameter molecular assays are
expensive and may not be widely available [34].
Nevertheless, for reimbursement decisions, there have
been strong efforts to enhance patient access to PM in
Europe [35]. Decision-analytic modeling demonstrating
cost effectiveness of combined test-treatment decisions
may, therefore, provide particularly important information
to decision makers and, potentially, improve accessibility
to PM. For example, the ISPOR Personalized Medicine
Special Interest Group notes that outcomes research and
economic modeling can inform the assessment of PM at
an early stage and supports prioritization of further re-
search by early-stage decision modeling of potential cost-
effectiveness and value of information (VOI) analyses [36].
Payne et al. derived recommendations to improve market
access for companion diagnostics. Economic modeling is
prescribed as a possible approach “to describe and quan-
tify gaps in the evidence base and the added value of fu-
ture research to reduce current uncertainties to support
the introduction of companion diagnostics” [37].
The role of patient involvement has changed in recent
years such that patients are increasingly included in the clin-
ical decision making process. Therefore, personalized treat-
ment has to account more actively for patient preferences
and their individual state of health [4]. For decision-analytic
modeling, as demonstrated in this study, future models
should allow for patient-specific utility values. Further re-
search in the field of companion diagnostics has identified
an additional contribution of complementary diagnostics
that goes beyond the usual health gains and cost savings. It
highlights for example the value to the patient of having
greater certainty of treatment benefit [38]. The upcoming
publication of the EPEMED OHE study 2015 (European
Personalized Medicine Association, Office of Health
Economics) will provide insights on “how to articulate a
value based evaluation per its economic, medical and full
social appreciation and how a broader conception of value
can be the path toward improving the HTA process” [39].
Conclusion
Our decision analysis shows that in the Austrian setting,
chemotherapy is usually effective and potentially cost ef-
fective for patients classified as intermediate or high risk
according to ODX, independent from their AO risk clas-
sification. Without information from the genetic test
ODX, chemotherapy would be assumed to be cost ef-
fective in intermediate and high risk patients per AO.
However, there are specific risk groups (I-L, H-L) only
identified by the genetic test that, on average, do not
benefit from chemotherapy. Our analysis suggests that
risk-group specific cost-effectiveness analyses that in-
clude the costs of companion diagnostics, including
prognostic tests, are important in PM.
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